- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape | 3 | Benzinga.com | ||
| 11.02. | Morgan Stanley cuts Third Harmonic stock rating amid uncertainty | 4 | Investing.com | ||
| THIRD HARMONIC BIO Aktie jetzt für 0€ handeln | |||||
| 11.02. | Third Harmonic stock rating cut by Raymond James | 3 | Investing.com | ||
| 11.02. | Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects | 1 | FierceBiotech | ||
| 11.02. | Aktien von Third Harmonic Bio brechen nach klinischen Studienergebnissen ein | 6 | Investing.com Deutsch | ||
| 11.02. | Third Harmonic Bio stock tumbles after clinical trial results | 1 | Investing.com | ||
| 11.02. | Third Harmonic Bio progresses THB335 to Phase 2 trial | 2 | Investing.com | ||
| 11.02. | Third Harmonic Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.01. | Third Harmonic Bio-Aktie erreicht 52-Wochen-Tief bei 5,58 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.01. | Aktien von Third Harmonic Bio fallen auf Tiefststand seit 2023 | 9 | Investing.com Deutsch | ||
| 13.01. | Third Harmonic Bio shares drop to lowest since 2023 | 8 | Investing.com | ||
| 10.01. | Aktie von Third Harmonic Bio erreicht 52-Wochen-Tief bei 8,04 US-Dollar | 1 | Investing.com Deutsch | ||
| 07.11.24 | Third Harmonic Flat on Q3 Results | - | Baystreet.ca | ||
| 07.11.24 | Third Harmonic Bio Announces Third Quarter 2024 Financial Results | 195 | GlobeNewswire (Europe) | THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO... ► Artikel lesen | |
| 07.11.24 | Third Harmonic Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.24 | Third Harmonic Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 31.10.24 | BVF Partners verkauft Aktien von Third Harmonic Bio im Wert von 14,3 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 30.10.24 | Medizinischer Leiter von Third Harmonic Bio verkauft Aktien im Wert von 40.095 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09.24 | Third Harmonic Bio executive sells shares worth over $71,000 | 2 | Investing.com | ||
| 10.09.24 | Third Harmonic Bio to Participate in Upcoming Investor Conferences in September | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,520 | -0,35 % | Evotec-Aktie kann Vortagsniveau nicht halten (8,49 €) | An der deutschen Börse liegt die Evotec-Aktie derzeit im Minus. Der jüngste Kurs betrug 8,49 Euro. Am Aktienmarkt liegt die Evotec-Aktie aktuell im Minus. Das Wertpapier verbilligte sich um 24 Cent.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,965 | +1,47 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,800 | +0,58 % | Viking Therapeutics jumps amid renewed takeover speculation | ||
| GALAPAGOS NV | 25,500 | -0,31 % | Galapagos NV: Galapagos receives transparency notification and 13D filing from Tang Capital | Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.
Pursuant to... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,310 | +1,31 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 0,763 | +2,01 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update | - Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated... ► Artikel lesen | |
| CYTOKINETICS | 47,200 | -2,07 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 14, 2025 it granted stock options to purchase an aggregate... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,780 | -1,02 % | Spero Therapeutics Aktie: Stillstand oder stabiler Kurs? | Die Spero Therapeutics Aktie verzeichnet aktuell einen leichten Rückgang von 0,68 Prozent auf 0,831 USD (Stand: 22. Februar 2025). Mit einer Marktkapitalisierung von 42,5 Millionen Euro bewegt sich... ► Artikel lesen | |
| TELO GENOMICS | 0,051 | +50,00 % | Telo Genomics Corp.: Telo Genomics Closes Oversubscribed $2.5 Million Private Placement | Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release... ► Artikel lesen | |
| ROIVANT SCIENCES | 10,220 | -0,05 % | Roivant Sciences Ltd. - 8-K, Current Report | ||
| LISATA THERAPEUTICS | 2,380 | +2,59 % | Lisata Therapeutics, Inc.: Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025 | ||
| MINERVA NEUROSCIENCES | 1,830 | +3,39 % | Minerva Neurosciences-Aktie erreicht 52-Wochen-Tief bei 1,86 US-Dollar | ||
| NEXTCURE | 0,761 | +10,13 % | NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers | BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class... ► Artikel lesen | |
| BOLT BIOTHERAPEUTICS | 0,476 | -1,76 % | Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. | -- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development... ► Artikel lesen | |
| KEZAR LIFE SCIENCES | 5,900 | +0,85 % | XFRA IVH,PR9,U04,6L00,2KZ0,W2B,MI70,1IY0,B1Q,PI6: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
THIRD HARMONIC BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,07 % bei einem Aktienkurs von 3,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THIRD HARMONIC BIO INC finden Sie auf Wallstreet Online.
